AI Healthcare Tech Revolution Drives $22 Billion Surge as Automation Transforms Medicine

Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – Healthcare AI technology platforms are experiencing unprecedented adoption as diagnostic markets surge at 22% annually across imaging, drug discovery, and clinical workflows to combat critical shortages of 40,000 radiologists and 11 million healthcare workers by 2030. Healthcare automation secured massive institutional backing this month when Medallion raised $43 million for AI-powered administrative automation while EliseAI captured $250 million to tackle the $600 billion in annual U.S. healthcare administrative costs. Clinical trials automation now explodes at 20-25% growth as pharmaceutical giants abandon manual workflows for intelligent systems that slash development timelines and reduce the $2.5 billion cost of bringing drugs to market. This transformation positions healthcare technology and automation leaders like Avant Technologies, Inc. (OTCQB: AVAI), OneMedNet Corporation (NASDAQ: ONMD), Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Oracle Corporation (NYSE: ORCL), and BioXcel Therapeutics, Inc. (NASDAQ: BTAI).
AI applications create $350-410 billion in annual pharmaceutical value by 2025 as intelligent automation enables companies to analyze millions of diagnostic images and potential treatments daily rather than traditional manual processes taking years. Major institutional players recognize this seismic shift as AstraZeneca, Pfizer, and Sanofi announce multibillion-dollar AI partnerships, creating extraordinary opportunities for early-positioned companies before massive institutional capital floods this rapidly evolving automation market.
Avant Technologies, Inc. (OTCQB: AVAI) and joint venture partner Ainnova Tech have substantially accelerated their FDA approval pathway for Vision AI by implementing an enhanced patient recruitment strategy targeting approximately 1,000 multiethnic patients across 8-10 U.S. clinical sites for their AI-powered diagnostic tool that can detect diabetic retinopathy in minutes without requiring an eye specialist on-site. This recruitment initiative leverages Fortrea, a globally recognized contract research organization with specialized ophthalmology expertise, to capture patient data primarily from community clinics and primary care facilities. Such an approach generates real-world evidence that regulatory agencies increasingly value while simultaneously validating commercial viability in diverse healthcare settings.
The regulatory foundation appears increasingly solid following Ainnova's mid-July pre-submission meeting with the FDA, where agency officials provided specific guidance on study design and compliance requirements. The refined clinical trial protocol addressing all FDA feedback has been submitted to Fortrea for final review, establishing a clear regulatory pathway toward FDA 510(k) clearance for domestic market entry.
"By focusing on community clinics and targeting a multiethnic group of around 1,000 diabetic patients, we aim to ensure that our study accurately represents the diverse population affected by diabetic retinopathy," explained Vinicio Vargas, CEO at Ainnova and Board member of Ai-nova Acquisition Corp. (AAC). "Working with Fortrea, an expert CRO in ophthalmology, allows us to confidently navigate this process with a partner that shares our commitment to quality and efficiency. We are getting closer to initiating a clinical study that will significantly contribute to obtaining FDA 510(k) approval and making our Vision AI platform a crucial tool in early disease detection."
Commercial traction is already demonstrable across international markets. Vargas recently presented breakthrough results from a Q4 2024 pilot collaboration with Roche and Salud 360 at Roche's "Macular Spectacular" conference in Colombia, showcasing expansion potential across the U.S., Canada, and Europe.
The technology has already gone live through Grupo Dökka's Fischel and La Bomba pharmacy chains, delivering walk-in screenings with real-time AI results while eliminating onsite ophthalmologist requirements.
This proven pharmacy deployment model is attracting significant interest from insurers and life sciences partners who recognize Vision AI's potential to transform preventive care delivery economics. The platform addresses critical healthcare access gaps while creating sustainable revenue streams for retail healthcare providers.
The market opportunity appears substantial. Diabetic retinopathy affects 9.6 million Americans within a US$3.25 billion U.S. market that analysts project will nearly double to US$6.1 billion by 2033. Avant maintains worldwide licensing rights to Ainnova's platform through AAC, positioning successful U.S. market entry as a potentially transformative commercial catalyst.
Vision AI's success could establish Ainnova as a leader in AI-powered disease detection. The company's expanding development roadmap includes cloud-connected retinal cameras for rural healthcare settings and innovative modules targeting Alzheimer's, cardiovascular conditions, and other chronic diseases through advanced retinal and blood biomarker analysis.
Avant continues evaluating a strategic acquisition of Ainnova Tech under a previously announced non-binding LOI, which could consolidate breakthrough AI healthcare technologies and proven leadership within a single public entity. Management has also indicated plans for a dedicated therapeutic-focused spinout, creating multiple potential value creation pathways within the expanding AI-driven healthcare transformation.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
OneMedNet Corporation (NASDAQ: ONMD) expanded its partnership with one of the world's top five medical device leaders through four distinct purchase orders under an evergreen master services agreement with no fixed term. The AI-powered Real-World Data company leverages its iRWD™ platform encompassing over 1,750 healthcare sites and 136 million clinical exams to deliver regulatory-grade multimodal data for medical imaging AI model development. OneMedNet has begun fulfilling these revenue-generating orders, demonstrating rapid execution from agreement to delivery.
"OneMedNet is uniquely positioned to deliver not only advanced medical imaging data but also the full depth of patient histories and provider notes from our partners’ electronic health records," said Aaron Green, President and CEO of OneMedNet. “Our ability to provide the most current, large-scale data across our growing partner network is what continues to drive repeat business and long-term customer trust.”
The company continues revolutionizing healthcare data access across rare diseases, oncology, and cardiology while expanding into financial services, retail, and telecommunications markets. OneMedNet's growing network of provider partnerships and subscription revenue model positions the platform for accelerated market penetration and sustained growth.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 2025 financial results with total revenue of $19.2 million compared to $14.4 million in Q2 2024, while advancing multiple clinical programs including REC-1245 and REC-617 through Phase 1/2 trials. The clinical-stage TechBio company maintains $533.8 million in cash and expects its runway to extend into Q4 2027, supporting its mission to decode biology through one of the world's largest proprietary biological and chemical datasets. Recursion continues leveraging its sophisticated machine-learning algorithms and massive computational scale through partnerships with Sanofi, Roche, Genentech, Bayer, and Merck KGaA.
"The power of our platform not only allows us to discover and develop potential new medicines, but also gives us insights on patient populations to target that would be challenging using traditional methods,” said Chris Gibson, Co-Founder and CEO of Recursion. “In discovery, we’re deploying advanced models like Boltz-2 to rapidly design ligands for high-value targets. State of the art platform capabilities helped us drive our fourth partnered discovery milestone with Sanofi this quarter, reflecting tangible momentum across our joint pipeline. We are leveraging these and other improvements to the Recursion OS to not only accelerate and improve our funnel of new programs, but also execution of later stage programs in our pipeline like RBM39 and CDK7.”
The company expects over $100 million in partnership milestones by end of 2026 while advancing several programs toward development candidate designation over the next 12-15 months. Recursion's Recursion OS 2.0 platform continues driving drug discovery innovation across oncology, immunology, and neuroscience applications.
Chime Financial, Inc. (NASDAQ: CHYM) recently announced a strategic partnership with Workday, Inc. (NASDAQ: WDAY) to integrate Chime Workplace™ financial wellness solutions with Workday Wellness, making financial wellness a core pillar of employee benefits. The partnership leverages Chime's 8.7 million member base and comprehensive financial tools including money management, savings, and credit building capabilities through Workday's AI-powered benefits platform.
"Employees today are increasingly looking to their employers for competitive financial wellness benefits," said Cristina Goldt, general manager, HCM, workforce management and payroll, Workday.
Workday customers can now enable Chime Workplace benefits directly through Workday Wellness for frictionless rollout within existing HR systems. Both Chime Workplace and Workday Wellness were recently named 2025 Top HR Products of the Year by HR Executive and HR Tech conference for their innovative workforce transformation solutions.
"Employers are increasingly seeking holistic, no-cost financial wellness solutions that serve every employee," said Jason Lee, Chief of Chime Enterprise, Chime.
Oracle Corporation (NYSE: ORCL) launched its next-generation EHR built from the ground up with AI technology, now available for ambulatory providers in the U.S. with acute care functionality planned for 2026. The cloud-native Oracle Health EHR features voice-first capabilities enabling clinicians to use conversational commands for patient information while leveraging AI agents trained on clinical concepts including conditions, lab results, and medications.
"While our competitors seem content with bolting features onto antiquated technology, we took on the enormous and highly complex challenge of creating an entirely new EHR, built in the cloud for the Agentic AI era," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “This is the future of intelligent care, where our healthcare providers are freed from technical baggage so they can focus on caring, connecting, healing, and preventing illness.”
Oracle designed the platform in partnership with front-line providers to reduce administrative burden and restore focus on patient care through personalized, streamlined workflows. The company's AI-driven platform operates on Oracle Cloud Infrastructure with semantic AI foundation supporting third-party integrations and custom agent development.
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) announced database lock completion for its SERENITY At-Home pivotal Phase 3 safety trial evaluating acute treatment of agitation associated with bipolar disorders or schizophrenia in at-home settings. The biopharmaceutical company collected data from more than 2,600 agitation episodes across 200+ patients at 22 sites nationwide, with topline results expected soon.
"The database lock is a significant step forward, and we are thrilled to have reached this critical milestone in an efficient manner as we look forward to reporting top-line results from the SERENITY At-Home pivotal Phase 3 safety trial soon," said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics.
BioXcel Therapeutics utilizes artificial intelligence to develop transformative neuroscience medicines, with BXCL501 representing the first potential FDA-approved therapy for acute agitation treatment in at-home settings. The company continues advancing BXCL501, which has received FDA Fast Track Designation, toward potential regulatory approval for addressing significant unmet medical needs in neuroscience care.
CONTACT:
Baystreet.ca
(250) 999-4849
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.